| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
313.95(M) |
| Last
Volume: |
1,560,200 |
Avg
Vol: |
2,306,261 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
92,653 |
92,653 |
204,995 |
510,803 |
| Total Sell Value |
$124,554 |
$124,554 |
$194,453 |
$1,231,647 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
4 |
13 |
34 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2024-05-17 |
4 |
S |
$1.75 |
$12,871 |
D/D |
(7,355) |
257,670 |
|
- |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-05-17 |
4 |
S |
$1.75 |
$10,955 |
D/D |
(6,260) |
230,414 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2024-05-17 |
4 |
S |
$1.75 |
$29,138 |
D/D |
(16,650) |
863,239 |
|
- |
|
| Kroin David |
|
– – • |
2024-05-10 |
4 |
S |
$1.78 |
$99,630 |
I/I |
(56,000) |
18,344,000 |
|
0% |
|
| Kroin David |
|
– – • |
2024-03-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
18,400,000 |
|
99% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-02-20 |
4 |
S |
$0.68 |
$5,172 |
D/D |
(7,606) |
236,674 |
|
-164% |
|
| Robin Howard W |
President & CEO |
• • – |
2024-02-20 |
4 |
S |
$0.68 |
$13,622 |
D/D |
(20,033) |
879,889 |
|
-164% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2024-02-20 |
4 |
S |
$0.68 |
$6,130 |
D/D |
(9,014) |
265,025 |
|
-164% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2023-11-17 |
4 |
S |
$0.49 |
$3,518 |
D/D |
(7,179) |
243,780 |
|
-88% |
|
| Robin Howard W |
President & CEO |
• • – |
2023-11-17 |
4 |
S |
$0.49 |
$9,740 |
D/D |
(19,877) |
899,922 |
|
-88% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2023-11-17 |
4 |
S |
$0.49 |
$4,727 |
D/D |
(9,646) |
274,039 |
|
-88% |
|
| Ajer Jeffrey Robert |
Director |
– • – |
2023-09-18 |
4 |
S |
$0.69 |
$3,008 |
D/D |
(4,359) |
34,153 |
|
26% |
|
| Myriam Curet |
Director |
– • – |
2023-09-18 |
4 |
S |
$0.69 |
$3,008 |
D/D |
(4,359) |
27,418 |
|
26% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2023-08-16 |
4 |
S |
$0.78 |
$7,568 |
D/D |
(9,703) |
283,685 |
|
34% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2023-08-16 |
4 |
S |
$0.78 |
$5,632 |
D/D |
(7,221) |
250,959 |
|
34% |
|
| Robin Howard W |
President & CEO |
• • – |
2023-08-16 |
4 |
S |
$0.78 |
$15,598 |
D/D |
(19,998) |
919,799 |
|
34% |
|
| Whitfield Roy A |
Director |
– • – |
2023-06-14 |
4 |
AS |
$0.57 |
$17,100 |
D/D |
(30,000) |
216,250 |
|
-13% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2023-05-16 |
4 |
S |
$0.72 |
$5,431 |
D/D |
(7,543) |
257,680 |
|
14% |
|
| Robin Howard W |
President & CEO |
• • – |
2023-05-16 |
4 |
S |
$0.72 |
$14,660 |
D/D |
(20,361) |
939,797 |
|
14% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2023-05-16 |
4 |
S |
$0.72 |
$7,050 |
D/D |
(9,791) |
293,388 |
|
14% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2023-02-16 |
4 |
S |
$3.00 |
$31,452 |
D/D |
(10,484) |
303,179 |
|
81% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2023-02-16 |
4 |
S |
$3.00 |
$24,825 |
D/D |
(8,275) |
265,223 |
|
81% |
|
| Thomsen Jillian B. |
Chief Financial Officer |
• – – |
2023-02-16 |
4 |
S |
$3.00 |
$30,801 |
D/D |
(10,267) |
313,497 |
|
81% |
|
| Robin Howard W |
President & CEO |
• • – |
2023-02-16 |
4 |
S |
$3.00 |
$58,905 |
D/D |
(19,635) |
960,158 |
|
81% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2022-11-16 |
4 |
S |
$3.57 |
$31,023 |
D/D |
(8,690) |
272,498 |
|
82% |
|
913 Records found
|
|
Page 1 of 37 |
|
|
